FGL1 Human
Fibrinogen-like protein 1, HP-041, Hepassocin, Hepatocyte-derived fibrinogen-related protein 1, HFREP-1, Liver fibrinogen-related protein 1, LFIRE-1, FGL1, HFREP1.
Greater than 90.0% as determined by SDS-PAGE.
THE BioTek's products are furnished for LABORATORY RESEARCH USE ONLY. They may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
Description
FGL1 Human Recombinant produced in E.Coli is a single, non-glycosylated, polypeptide chain (a.a 23-312) containing 300 amino acids including a 10 a.a N-terminal His tag. The total molecular mass is 35.3kDa (calculated).
Product Specs
Fibrinogen-like protein 1, HP-041, Hepassocin, Hepatocyte-derived fibrinogen-related protein 1, HFREP-1, Liver fibrinogen-related protein 1, LFIRE-1, FGL1, HFREP1.
MKHHHHHHAS LEDCAQEQMR LRAQVRLLET RVKQQQVKIK QLLQENEVQF LDKGDENTVI DLGSKRQYAD CSEIFNDGYK LSGFYKIKPL QSPAEFSVYC DMSDGGGWTV IQRRSDGSEN FNRGWKDYEN GFGNFVQKHG EYWLGNKNLH FLTTQEDYTL KIDLADFEKN SRYAQYKNFK VGDEKNFYEL NIGEYSGTAG DSLAGNFHPE VQWWASHQRM KFSTWDRDHD NYEGNCAEED QSGWWFNRCH SANLNGVYYS GPYTAKTDNG IVWYTWHGWW YSLKSVVMKI RPNDFIPNVI.
Product Science Overview
FGL1 plays a significant role in liver function. It can induce hepatocyte proliferation and aid in liver injury recovery by activating the epidermal growth factor receptor (EGFR)/EGFR kinase (ERK) and the Src-dependent pathway . This makes it a crucial protein in liver regeneration and repair processes.
Recent studies have highlighted FGL1 as a newly emerging checkpoint ligand of lymphocyte activation gene 3 (LAG3), emphasizing its potential as a target for immune checkpoint therapy . Immune checkpoints are essential in modulating the immune response and mediating T cell dysfunction in autoimmunity and inflammation . However, these inhibitory pathways can be exploited by tumor cells to promote immune escape .
The targeting of FGL1/LAG3 is considered the next generation of immune checkpoint therapy . This approach aims to reverse T cell exhaustion by targeting immune checkpoints, allowing cytotoxic T cells to attack tumor cells . This has significant implications for cancer treatment, especially in overcoming resistance to current therapies like anti-PD-1/PD-L1 monoclonal antibodies .
